These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33120121)

  • 1. DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.
    Rad AS; Ardjmand M; Esfahani MR; Khodashenas B
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Feb; 247():119082. PubMed ID: 33120121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ab Initio Insight into the Interaction of Metal-Decorated Fluorinated Carbon Fullerenes with Anti-COVID Drugs.
    Katin KP; Kochaev AI; Kaya S; El-Hajjaji F; Maslov MM
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metal oxide nanocage as drug delivery systems for Favipiravir, as an effective drug for the treatment of COVID-19: a computational study.
    Yao C; Xiang F; Xu Z
    J Mol Model; 2022 Feb; 28(3):64. PubMed ID: 35182223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adsorption of Celecoxib on B
    Abdolahi N; Aghaei M; Soltani A; Azmoodeh Z; Balakheyli H; Heidari F
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Nov; 204():348-353. PubMed ID: 29957413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The supramolecularly complexes of calix[4]arene derivatives toward favipiravir antiviral drug (used to treatment of COVID-19): a DFT study on the geometry optimization, electronic structure and infrared spectroscopy of adsorption and sensing.
    Yuksel N; Köse A; Fellah MF
    J Incl Phenom Macrocycl Chem; 2021; 101(1-2):77-89. PubMed ID: 34121921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
    Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
    Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metalloporphyrin reduced C70 fullerenes as adsorbents and detectors of ethenone; A DFT, NBO, and TD-DFT study.
    Jouypazadeh H; Arshadi S; Cespedes Panduro B; Kumar A; Habibzadeh S; Ahmadi S; Vessally E
    J Mol Graph Model; 2023 Jul; 122():108481. PubMed ID: 37146386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
    Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
    Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
    Doran MA; Aytogan H; Ayıntap E
    Virol J; 2021 Jul; 18(1):146. PubMed ID: 34256791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
    Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
    Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
    Ömeroğlu ŞK; Temel F; Altun D; Öztop B
    Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.